Approved Study Database

Ref. No. Scientific Title Principal investigator
2011.237 Management and Prognosis of Patients with Minor Coronary Artery Disease YAN Ping Yen Bryan
2011.234 Predicting Outcomes in Acute Coronary Syndrome: A Translational Approach Integrating Population-Specfic Clinical Risk Models, Platelet Reactivity and Metabolomic Biomarkers YAN Ping Yen Bryan
2012.131 Psychiatric Morbidity in Adult Patients with Cervical Dysplasia in a Colposcopy Clinica in Hong Kong YAN Tin Yee Connie
2005.262 Intervention of Drooling in Children with Neurological Disability YANG Li Chien Hellen (No email contact)
2007.507 Studies on a New Therapeutic Strategy to Enhance mRNA / Protein Expression of Endothelial Nitric Oxide Synthase (eNOS) and NO-related Function in Disease - Use of eNOS Enhancer YANG Qin
2004.313 To Test the Reliability of Richmond Agitation Sedation Score (RASS score) in an Adult ICU YAP Hui Yi Florence
2009.082 Prevalence of depressive disorder among Chinese chronic pain patients in Hong Kong YAP Jacqueline
2010.122 Detection of Patent Foramen Ovale in Young Patients with Stroke by Transthoracic Saline Contrast Echocardiography in Hong Kong Yat Yin LAM
2005.417 Effectiveness of Soft Versus Rigid Splinting Designs for First Carpometacarpal Joint Arthritis YAU Carmen
2006.148 Quality of Life of Nasopharyngeal Cancer (NPC) Patients at Diagnosis and 5+ years after Radical Radiotherapy; A Hong Kong Experience Using SF-36v2 and Norm-based Scoring Algorithm YAU Sau Han
2004.091 A Phase III, Randomized Open Label Multicenter Study Comparing GW572016 and Capecitabine (Xeloda) Versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Prof. Yeo Winnie
2003.030 A Phase 2 Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer Prof. Yeo Winnie
2006.263 Detection of Circulating Tumor Cells in Patients with Breast Cancer YEO Winnie
2002.469 A Randomized, Double-blind, Parallel-group Study Conducted Under In-house Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy (Revised : CRE-2002.321-T) Prof. Yeo Winnie
2005.369 Randomized Phase II Study of the Combination of Oral Vinorelbine With Capecitabine Versus A Sequential Regimen of Oral Vinorelbine and Capecitabine Versus the Combination of Docetaxel and Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines Prof. Yeo Winnie
2002.062 Randomized Double Blind Trial of Megestrol Acetate Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma: An Asia-Pacific Hepatocellular Carcinoma Trials Group Prof. Yeo Winnie
2006.205 An Open Label International Multi-Center Phase 2 Activity and Safety Study of SU011248 in Patients with Advanced / Metastatic Gastric Cancer Progressing or Recurring After One Prior Chemotherapy Prof. Yeo Winnie
2006.414 A Randomized, Double-Blind, Parallel Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy Prof. Yeo Winnie
2005.463 Novel Therapeutics Using Inhibitor of histone Deacetylation - PXD101 - by Targeting Epigenetic Biomarkers for Hepatocellular Carcinoma YEO Winnie
2006.226 A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women with ErbB2 Overexpressing Metastatic Breast Cancer Prof. Yeo Winnie
2005.418 A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer Prof. Yeo Winnie
2007.247 An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women with Advanced or Metastatic Breast Cancer Prof. Yeo Winnie
2002.433 Hepatitis B Virus-Related Complications of Cytotoxic Chemotherapy in Patients with Inoperable Hepatocellular Carcinoma Prof. Yeo Winnie
2005.020 A Phase II Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 When Administered as a Daily Doses of 50mg, 100mg and 150mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy Prof. Yeo Winnie
2006.355 A Randomized 2-Arm, Open-Label, Phase II Study of BMS-582664, Administered Orally at A Dose of 800mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Prof. Yeo Winnie
2003.164 Amonafide: Individual Phenotype-Adjusted Chemotherapy for Women with Metastatic Breast Cancer Who have Progressed Despite Prior Chemotherapy Prof. Yeo Winnie
2004.421 A Phase III Randomized, Double-Blind Study to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Adriamycin-Cyclophosphamide Adjuvant Chemotherapy in Chinese Breast Cancer Patients Prof. Yeo Winnie
2001.238 Randomised Double-blind Trial in Postmenopausal Women with Primary Breast Cancer Who Have Received Adjuvant Tamoxifen for 2-3 years, Comparing Subsequent Adjuvant Exemestane Treatment with Further Tamoxifen Prof. Yeo Winnie
2006.304 A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurkinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy Prof. Yeo Winnie
2002.111 Phase II Study of Gemcitabine/Carboplatin Combination Chemotherapy As First Line Therapy Or Recurrent Or Metastatis Breast Cancer Prof. Yeo Winnie
2007.199 An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Prof. Yeo Winnie
2006.230 An Open Label International Multi-Center Phase 2 Activity and Safety Study of SU011248 in Patients with Unresectable Hepatocellular Carcinoma YEO Winnie
2006.280 A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer Prof. Yeo Winnie
2002.394 An Open-Label Phase IIa Trial of Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients with Advanced Local or Metastatic Gastric Cancer Prof. Yeo Winnie
2005.197 An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL_/CAELYX_ and YONDELIS Prof. Yeo Winnie
2001.415 A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC_T) as Adjuvant Treatment of Operable Breast Cancer Her2neu Negative Patients with Positive Axillary Lymph Nodes Prof. Yeo Winnie
2005.288 A Phase I/II Study of PXD101 in Patients with Unresectable Hepatocellular Carcinoma With Pharmacokinetic and Pharmacodynamic Evaluation Prof. Yeo Winnie
2005.127 Detection of Tumour Suppressor Gene DLC1 in Hepatocellular Carcinoma YEO Winnie
2005.002 The Effectiveness of Psychosocial Intervention with Eastern Body-Mind-Spirit Approach in Enhancing the Quality of Life of Breast Cancer Patients YEO Winnie
2004.143 The Role of Drug Resistance Genes in Chemotherapy Resistance in Patients with Inoperable Hepatocellular Carcinoma - Analysis of Cytogenetic, Genetic and Clinical Factors YEO Winnie
2004.420 The Association of Pharmacogenetics and Chemotherapy-Induced Toxicities in Breast Cancer Patients Receiving Chemotherapy YEO Winnie
2007.001 Self Management and the Role of Pharmacists in Developing An Effective Primary Care System: Developing A Consensus Based Policy Framework YEOH Eng Kiong
2008.251 Hospital Authority Tender for the Study on Flagship Program on Reducing Avoidable Hospitalization YEOH Eng Kong
2004.030 An One-Year Audit of Patients Attending A Multidisciplinary Out-patient Pain Centre YEUNG Cheryl
2003.400 Comparison of Ketamine or Ketorolac for Postoperative Analgesia in Ambulatory Laparoscopic Sterilization Dr. Yeung Cheryl
2003.183 N.E.T. - Necrotizing Enterocolitis Trial Primary Peritoneal Drainage in Necrotizing Enterocolitis: Randomized Controlled Multi-Centre Trial Primary Peritoneal Drainage in Necrotizing Enterocolitis: Randomized Controlled Multi-Centre Trial Prof. Yeung Chung Kwong
2002.176 The Efficacy of Scaral Neuromodulation for the Adjunctive Treatment of Detrusor Underactivity in Children Prof. Yeung Chung Kwong
2002.444 Open Label Extension and Long Term Safety Study of Tolterodine PR Capsules in Children 5 to 11 Years of Age with Symptoms of Urge Urinary Incontinence Suggestive of Detrusor Instability Prof. Yeung Chung Kwong
2002.129 A Phase III, Randomized, Double Blind, Multicenter, Multinational Study To Determine The Efficacy And Safety Of Tolterodine Prolonged Release Capsules in Children 5-10 y With Symptoms of Urge Urinary Incontinence, Suggestive of Detrusor Instability Prof. Yeung Chung Kwong
2006.331 Surgical Outcome Analysis and Psychological Evaluation of Intersex Patients Managed Between 1993 and 1995 YEUNG CK

Page 43 of 262.